Testosterone isn't static. It fluctuates by time of day, by age, by body fat percentage — and by season. If you're a man on a GLP-1 medication, two separate lines of evidence converge right now to suggest your hormonal profile may be at its most favorable point of the year.
This isn't wellness speculation. It's data from a 27,328-man cohort study on seasonal testosterone variation and a separate 110-man analysis presented at the Endocrine Society's 2025 annual meeting on what GLP-1 medications do to male testosterone levels.
The implications for timing, treatment decisions, and lab interpretation are practical and immediate.
Testosterone Peaks in Summer: The 27,000-Man Study
In 2022, Zornitzki and colleagues published the largest study to date on seasonal testosterone variation in the International Journal of Endocrinology. They analyzed testosterone levels from 27,328 men aged 20–70 across all BMI categories and comorbidity profiles.
The finding was unambiguous: both total and bioavailable testosterone levels peaked in the August-October period (summer through early fall) and reached their lowest point in March (late winter). This seasonal pattern held after adjusting for age, BMI, diabetes, smoking, and cardiovascular disease — meaning the summer peak isn't just an artifact of being more active or spending more time outdoors.
A separate large-scale analysis by Santi and colleagues — examining 12,033 data points from 7,491 men — confirmed the same pattern: testosterone showed higher levels in summer with a direct correlation to environmental temperature and daylight duration.
The mechanisms aren't fully established, but three factors likely contribute:
- Vitamin D synthesis. Summer sun exposure drives vitamin D production, which is independently associated with higher testosterone levels. Multiple studies link vitamin D deficiency to hypogonadism.
- Increased physical activity. Men tend to be more active in summer months, and regular exercise — particularly resistance training — is one of the most reliable natural testosterone boosters.
- Light exposure and circadian regulation. Longer daylight hours affect the hypothalamic-pituitary-gonadal axis, potentially optimizing gonadotropin signaling and downstream testosterone production.
One important caveat: not all studies agree on the exact timing of the peak. A Norwegian cohort (Svartberg et al., 2003) found a bimodal pattern with peaks in both February and October-November, and a nadir in June. The inconsistency across studies may reflect geographic, latitude, and climate differences. But among the largest and most methodologically rigorous studies, the summer-autumn peak is the most consistently supported finding.
GLP-1 Medications Amplify the Effect: The ENDO 2025 Data
At ENDO 2025 — the Endocrine Society's annual meeting in San Francisco — Dr. Shellsea Portillo Canales presented results from an 18-month retrospective analysis of 110 men with obesity or type 2 diabetes who were treated with semaglutide, dulaglutide, or tirzepatide. None of the men were receiving testosterone replacement therapy.
The results:
| Metric | Baseline | 18 Months | Change |
|---|---|---|---|
| Normal total & free T | 53% | 77% | +24 percentage points |
| Average total T | 322 ng/dL | 380 ng/dL | +18% |
| Free testosterone | — | — | +17% |
| Body weight | 255 lbs | 229 lbs | -10% |
Dr. Sandeep Dhindsa, the study's senior investigator, emphasized that this wasn't just a total testosterone increase driven by rising SHBG (sex hormone-binding globulin, which naturally increases with weight loss). Free testosterone — the biologically active fraction — also rose by 17%, confirming a genuine improvement in hormonal status.
"Someone had to show that free testosterone is changing," Dhindsa stated at the conference. This distinction matters because total T can rise simply from SHBG increases without any real improvement in androgenic activity.
The Mechanism: Fat Loss Drives Testosterone Recovery
The relationship between adipose tissue and testosterone is bidirectional and vicious. Excess body fat — particularly visceral fat — converts testosterone to estradiol via the aromatase enzyme. Lower testosterone then promotes further fat storage, which creates more aromatase, which converts more testosterone. It's a self-reinforcing decline.
GLP-1 medications break this cycle through substantial visceral fat reduction. In the BELIEVE trial, the combination arm achieved a 58.2% reduction in visceral adipose tissue. Even semaglutide alone drove a 35.8% visceral fat reduction. Less visceral fat means less aromatase activity, which means more testosterone stays as testosterone.
"These findings suggest that in men with obesity or type 2 diabetes, incretin-based therapy may help restore healthy testosterone levels, particularly when low testosterone is related to obesity," Portillo Canales told Healthline.
GLP-1s vs. TRT: The Head-to-Head Data Men Need to See
Two recent clinical comparisons put GLP-1 medications directly against testosterone replacement therapy — and the results challenge the assumption that TRT is the superior option for obese men with low T.
2024 Slovenian Randomized Controlled Trial
In obese diabetic men with hypogonadism, semaglutide producing 6.5% weight loss generated a 1.6 nmol/L increase in total testosterone — matching TRT on testosterone improvement while delivering superior body composition changes.
2025 Italian Pilot Study (ENDO 2025)
In 83 obese hypogonadal men over 8 weeks, tirzepatide produced larger increases in both free and total testosterone compared to transdermal TRT, along with better body composition results and improved erectile function scores.
This doesn't mean TRT is obsolete. For men with primary hypogonadism (testicular failure), GLP-1s won't be sufficient because the problem isn't fat-mediated aromatization — it's insufficient testosterone production at the source. But for the large population of men whose low T is driven primarily by obesity, the data now suggests GLP-1 therapy may address the root cause rather than supplementing around it.
The Fertility Advantage
There's a critical distinction that younger men need to understand: TRT suppresses spermatogenesis. Exogenous testosterone shuts down the hypothalamic-pituitary-gonadal axis, reducing or eliminating sperm production — a well-documented effect that takes months to reverse after discontinuation.
GLP-1 medications don't do this. In fact, preliminary data from the ENDO 2025 studies suggest that by restoring endogenous testosterone production through weight loss, GLP-1 therapy actually supports natural reproductive function. One earlier study noted a 17% improvement in normal sperm morphology with semaglutide, compared to a 61% decline in sperm concentration with TRT.
For men in their 30s and 40s who want to improve testosterone without sacrificing fertility, the GLP-1 pathway is increasingly the evidence-based choice.
What This Means Right Now: Summer 2026
If you're a man on a GLP-1 medication and you get your testosterone checked this summer, your numbers are likely to look better than they would in any other season — for two independent reasons:
- Seasonal peak. Natural circannual testosterone variation puts your hormonal output at or near its highest from June through October.
- GLP-1 amplification. If you've been on therapy for several months, the fat loss–driven testosterone recovery is compounding on top of that seasonal advantage.
Practical Implications
- Lab timing awareness. If you're getting labs to evaluate whether you need TRT, know that a summer reading represents your seasonal best. A reading of 350 ng/dL in July might drop to 300 in March. Don't make TRT decisions based on a single summer value.
- GLP-1 duration matters. The ENDO 2025 data covered 18 months of therapy. Testosterone improvements are progressive — expect more significant changes at 6, 12, and 18 months than at 3 months.
- Resistance training magnifies the effect. Exercise independently boosts testosterone. Combined with GLP-1-driven fat loss and summer seasonal advantage, men who lift consistently through summer may see their strongest testosterone profile of the year.
- Visceral fat is the target. Not all fat loss is equal for testosterone. Visceral fat (the kind around your organs) is the primary driver of aromatase-mediated testosterone suppression. GLP-1 medications are particularly effective at reducing visceral adipose tissue.
- Don't undermine it with bad sleep. Summer's longer days and social schedules can disrupt sleep, which is when most testosterone is produced. Protect 7–8 hours per night even when it stays light until 9pm.
The Bottom Line
Two things are happening at once. Your body's natural hormonal rhythm is pushing testosterone toward its annual peak. And if you're on a GLP-1 medication, the progressive fat loss is independently driving testosterone recovery — potentially normalizing levels that haven't been in the healthy range for years.
The data from the largest seasonal testosterone study ever conducted (27,328 men) and the most recent GLP-1/testosterone analysis (ENDO 2025, 110 men over 18 months) tell the same story from different angles: summer is the season where biology is most on your side.
Use it. Train hard. Protect your sleep. And if you haven't had your testosterone checked recently, summer is the right time — just understand that you're seeing your seasonal best, and plan accordingly.
Ready to Start GLP-1 Treatment?
Compare telehealth providers that offer GLP-1 prescriptions with lab monitoring and ongoing hormone support.
Compare Providers Browse all guides · Updated for summer 2026Sources
- Zornitzki T, et al. "Seasonal Variation of Testosterone Levels in a Large Cohort of Men." International Journal of Endocrinology, 2022. PMC
- Santi D, et al. "Seasonal Changes of Serum Gonadotropins and Testosterone in Men Revealed by a Large Data Set of Real-World Observations Over Nine Years." Frontiers in Endocrinology, 2019. PMC
- Portillo Canales S, et al. "Anti-obesity medications can normalize testosterone levels in men." Presented at ENDO 2025, San Francisco, CA, July 14, 2025. Endocrine Society
- Dhindsa S, et al. Retrospective cohort study of 234 men on incretin-based therapy. Presented at ENDO 2025. Healio
- Heymsfield SB, et al. "Bimagrumab and semaglutide alone or in combination for the treatment of obesity: a phase 2 randomized clinical trial." Nature Medicine, March 2026. Nature
- Svartberg J, et al. "Seasonal Variation of Testosterone and Waist to Hip Ratio in Men: The Tromsø Study." J Clin Endocrinol Metab, 88(7):3099–3104, 2003.
- Healthline. "GLP-1 Drugs May Boost Testosterone Levels In Men." July 2025. healthline.com
- Pruski D. "Do GLP-1s Kill Your Testosterone?" May 2026. Slovenian RCT and Italian pilot study review. Substack
Medical Disclaimer: This content is for informational purposes only and is not a substitute for professional medical advice. Testosterone levels should be interpreted by a qualified healthcare provider. Do not start, stop, or modify any medication — including TRT — based on this article alone.
FDA Notice: Compounded medications are not FDA-approved. Only brand-name GLP-1 medications (Wegovy, Zepbound, Ozempic, Mounjaro) carry FDA approval for their indicated uses.